Company Profile
Nanjing Cellnuo Biopharmaceutical Co., Ltd. is a fully owned subsidiary of Nanjing Cellnuo Biotechnology Co., Ltd. and is a leading biotechnology company in China. The team has over 20 years of R&D, production, and management experience in top enterprises. The company’s pharmaceutical division focuses on the development of diabetes biopharmaceuticals, using genetic engineering to produce insulin and GLP-1 class biopharmaceuticals, and also developing other biopharmaceuticals. Actively exploring stem cell therapy and the new approach of intestinal microorganism therapy for diabetes, it has received funding from well-known professional companies and government-guided funds in the field of diabetes treatment in China, and related cutting-edge technologies have been supported by laboratories in Germany and the United States.
Another division of the company is focused on providing global pharmaceutical companies, cell culture companies, and research institutes with high-quality, high-stability recombinant proteins, enzymes, and other factor-like products, as well as high-level technical services. The company can complete gene synthesis to gram-level products and complete process plans in as little as 2-3 weeks, especially in optimizing protein products with high technical difficulty and cost limitations. It has long been committed to product standardization, operational standardization, and quality management standardization, and is currently one of the leading enterprises in the production of recombinant proteins, enzymes, and growth factors worldwide. The company has now become a strategic partner of many well-known enterprises and top enterprises.
Company history
In December 2018, Nanjing Cellnuo Biotechnology Co., Ltd. was established and received angel round investment.
In June 2019, the first product process was successfully put into production at a scale of 1000L.
In February 2020, a fully owned subsidiary, Nanjing Cellnuo Biopharmaceutical Co., Ltd., was established in Jiangbei New Area, Nanjing.
In March 2020, Cellnuo Biotechnology received Pre-A round investment, and the Cellnuo Biotechnology protein drug screening platform was established in Jiangbei, Nanjing.
In January 2021, the 1600 square meter CMC laboratory in Jiangbei was put into operation.
In June 2021, the 1100 square meter GMP-compliant pilot plant in Jiangbei was constructed.
In August 2022, the biological similar drug SN001 IND project was successfully completed, and the pre-research for the biological new drug SN006 project obtained good results.
Our advantage
Leading technical platform
In the field of biopharmaceuticals, the company has a comprehensive biotechnology platform, mainly as follows:
- Protein evolution platform: protein directed evolution, protein engineering design based on AI/crystal structure.
- Efficient cell expression technology: based on promoter modification, fusion protein and target protein matching research and AI predicted expression research.
- Protein variant and isoform technology: based on complex proteins, multi-disulfide bond protein/enzyme variant oxidative reduction conditions and molecular companion multi-system research.
- Large-scale production platform: development of complex processes on a scale of more than 1000L, large-scale process amplification and production platform technical capabilities.
- These platforms can not only play their advantages in the field of drugs, but also play a strong driving role in the industrial protein production. At the same time, the company has also built a platform for the optimization of the prescription process for biological similar drugs and the development and evaluation of the prescription of biological new drugs. Based on the above platforms, the company can undertake the research and development and process optimization of various microorganism-expressed proteins and peptide drugs. It can also provide a variety of high-end industrial products based on this drug platform.
The industrial product platforms are as follows：
- Efficient prokaryotic cell expression platform, mammalian cell expression platform, insect cell expression platform, yeast cell expression platform.
Rich research and production experience
The company’s upstream and downstream process development team has accumulated rich experience in both pharmaceuticals and industrial products through years of technological accumulation. It has mature expression research and technical platforms, mature protein purification preparation platforms, and mature protein structure-function mechanism research platforms. In particular, in the field of high-end industrial protein products, the company has long been committed to optimizing production processes, improving product quality, protein activity and yield research, using raw materials and technologies suitable for large-scale production, providing stable downstream processes and quality research and document system construction suitable for pharmaceutical process development needs. Our products and services include monoclonal antibodies, recombinant proteins, fusion proteins, cytokines and growth factor protein drugs and industrial products purification and services, including but not limited to the following:
- Development of different host expression platforms (E. coli, mammalian cells and Bacillus subtilis);
- Development and optimization of chromatographic purification processes (affinity chromatography, ion exchange chromatography, hydrophobic chromatography, mixed mode chromatography);
- Protein CMC quality evaluation system that meets the requirements of biological raw materials and stable activity and purity output protein products;
- Technology transfer at pilot scale and 100L level;
- Protein activity analysis and quality platform capability that meets GMP requirements.
Company culture
Dedicated to the development of diabetes biopharmaceuticals
Innovation, self-motivation, teamwork, win-win